Day

Hour

Minute

Second

BioNTech & BMS Show Strong Lung Cancer Efficacy

Akeso Delivers Phase 3 Survival Win in NSCLC

Pfizer & Innovent Double Down on Multispecifics

FDA Approves HER2/HER3 Bispecific in Solid Tumours

Regeneron Expands $2B+ CytomX Bispecific Pact

Jazz & AbCellera Ink $4B Antibody Alliance

Leveraging Mechanistic Modelling Approaches for Dose Selection to Derisk Clinical Development & Elevating the Need for Biomarker-Driven Patient Selection Strategies to Diversify Therapeutic Area Applications